[go: up one dir, main page]

GB201007187D0 - Ubiquitination modulators - Google Patents

Ubiquitination modulators

Info

Publication number
GB201007187D0
GB201007187D0 GBGB1007187.6A GB201007187A GB201007187D0 GB 201007187 D0 GB201007187 D0 GB 201007187D0 GB 201007187 A GB201007187 A GB 201007187A GB 201007187 D0 GB201007187 D0 GB 201007187D0
Authority
GB
United Kingdom
Prior art keywords
ubiquitination
modulators
ubiquitination modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1007187.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ITI Scotland Ltd
Original Assignee
ITI Scotland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ITI Scotland Ltd filed Critical ITI Scotland Ltd
Priority to GBGB1007187.6A priority Critical patent/GB201007187D0/en
Publication of GB201007187D0 publication Critical patent/GB201007187D0/en
Priority to PCT/GB2011/000658 priority patent/WO2011135303A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1007187.6A 2010-04-29 2010-04-29 Ubiquitination modulators Ceased GB201007187D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1007187.6A GB201007187D0 (en) 2010-04-29 2010-04-29 Ubiquitination modulators
PCT/GB2011/000658 WO2011135303A2 (en) 2010-04-29 2011-04-28 Ubiquitination modulators

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1007187.6A GB201007187D0 (en) 2010-04-29 2010-04-29 Ubiquitination modulators

Publications (1)

Publication Number Publication Date
GB201007187D0 true GB201007187D0 (en) 2010-06-09

Family

ID=42271047

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1007187.6A Ceased GB201007187D0 (en) 2010-04-29 2010-04-29 Ubiquitination modulators

Country Status (2)

Country Link
GB (1) GB201007187D0 (en)
WO (1) WO2011135303A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344555B (en) 2007-05-08 2016-12-20 Hunter Douglas Ind Switzerland Multivariate color system with texture application.
GB201007185D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination assay
BR102013022402B1 (en) * 2013-09-02 2020-09-15 Universidade Federal Do Rio Grande Do Sul BENZYLTHIAZOLIDINONIC DERIVATIVES USEFUL IN TREATING SCHIZOPHRENIA
AU2015265865C1 (en) 2014-05-28 2025-01-30 Universitat Bern Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
CN107089978A (en) * 2016-02-17 2017-08-25 复旦大学 Thiazolidinone derivatives and its production and use
KR101940994B1 (en) 2016-12-23 2019-01-23 (주)위즈켐 The preparation method of 4’-formyl-4-biphenylcarboxylic acid
CN107383147A (en) * 2017-07-14 2017-11-24 广东食品药品职业学院 A kind of Sitosterolum and Epalrestat conjugate and its production and use
EP3651747A4 (en) 2017-11-17 2020-07-22 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders
CR20200441A (en) 2018-02-27 2021-03-15 Incyte Corp Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
US10730874B2 (en) 2018-03-13 2020-08-04 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein and uses thereof
MX2020012376A (en) 2018-05-18 2021-03-09 Incyte Corp Fused pyrimidine derivatives as a2a / a2b inhibitors.
IL279829B2 (en) 2018-07-05 2025-05-01 Incyte Holdings Corp Fused pyrazine derivatives as a2a / a2b inhibitors
KR102348468B1 (en) * 2018-08-30 2022-01-07 서울대학교산학협력단 Human NADP-dependent steroid dehydrogenase-like (NSDHL) enzyme inhibitors and pharmaceutical composition for use in preventing or treating cancer or hypercholesterolemia containing the same as an active ingredient
WO2020046020A1 (en) * 2018-08-30 2020-03-05 서울대학교산학협력단 Inhibitory material against human body-derived nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like, and anticancer agent comprising same as effective ingredient or pharmaceutical composition comprising same as effective ingredient for treatment of hyperlipidemia
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
EP4031245A1 (en) 2019-09-18 2022-07-27 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
JP7777519B2 (en) 2019-09-18 2025-11-28 武田薬品工業株式会社 Plasma kallikrein inhibitors and uses thereof
CN115236338B (en) * 2021-04-23 2024-09-10 四川大学 Application of beta-TrCP 1 detection reagent in preparation of ulcerative colitis screening kit

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
US20050282840A1 (en) * 2004-02-11 2005-12-22 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
WO2006002284A1 (en) 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US20070099970A1 (en) * 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain

Also Published As

Publication number Publication date
WO2011135303A2 (en) 2011-11-03
WO2011135303A3 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
GB201007187D0 (en) Ubiquitination modulators
DK3342786T3 (en) Anti-dll3-antistof
AP3107A (en) 5-Alkynyl-pyrimidines
EP2566479A4 (en) Azaindazoles
EP2640189A4 (en) 3-deutero-pomalidomide
DK3466977T3 (en) Anti-vla-4-antistoffer
EP2562212A4 (en) Hydrogel
EP2641891A4 (en) Pkc- activator
GB201001760D0 (en) Dipenser
GB201001385D0 (en) Cable-tidies
GB201001546D0 (en) Knocktop
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
AU4937P (en) FlatinsulGL Myoporum insulare
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
AU4536P (en) TB01 Tibouchina urvilleana
TWM387087U (en) can
GB201003529D0 (en) eezy one
GB201001057D0 (en) Versa-pod
GB201000020D0 (en) Velcrose
GB201000203D0 (en) Formits
GB201000246D0 (en) Head-kase
GB201000262D0 (en) Flexishaft
GB201000426D0 (en) Earbling
GB201000547D0 (en) Jurasic

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)